Evaluation of the antiretroviral effects of a PEG-conjugated peptide derived from human CD38

Expert Opinion on Therapeutic Targets

Volumn 13, Issue 2, 2009, Pages 141-152

  Bensi, Thea ^a   Mele, Federico ^b   Ferretti, Massimo ^a   Norelli, Sandro ^b   El Daker, Sary ^b   Chiocchetti, Annalisa ^a   Rojo, Josè Maria ^c   Cauda, Roberto ^d   Dianzani, Umberto ^a   Savarino, Andrea ^b  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^d CATHOLIC UNIVERSITY   (Italy)

Author keywords

Antiretroviral; CD38; CD4; gp120; MTT assay; Protein protein interaction; Therapeutic peptide

Indexed keywords

AMINO ACID; ANTIRETROVIRUS AGENT; CD38 ANTIGEN; CD4 ANTIGEN; GLYCOPROTEIN GP 120; LYSINE; MACROGOL; SOLUBLE CD38 PEPTIDE; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; MACROGOL DERIVATIVE;

AMINO ACID SEQUENCE; ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; BINDING SITE; CELL STRAIN; COCULTURE; COMPUTER MODEL; CONJUGATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CONJUGATION; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MOUSE; NONHUMAN; T LYMPHOCYTE; VIRUS ENVELOPE; VIRUS REPLICATION; ANIMAL; CELL LINE; CHEMISTRY; GIANT CELL; METABOLISM; TUMOR CELL LINE; VIROLOGY;

ANIMALS; ANTI-HIV AGENTS; ANTIGENS, CD38; ANTIGENS, CD4; BINDING SITES; CELL LINE; CELL LINE, TUMOR; COCULTURE TECHNIQUES; GIANT CELLS; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; MICE; POLYETHYLENE GLYCOLS; T-LYMPHOCYTES; VIRUS REPLICATION;

EID: 64349123327     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728220802637147     Document Type: Article

References (36)

1. Malavasi F, Deaglio S, Funaro A, et al. Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol Rev 2008;88:841-886
2. Zubiaur M, Fernandez O, Ferrero E, et al. CD38 is associated with lipid rafts and upon receptor stimulation leads to Akt/protein kinase B and Erk activation in the absence of the CD3-zeta immune receptor tyrosine-based activation motifs. J Biol Chem 2002;277:13-22 (Pubitemid 34952022)
3. Partida-Sanchez S, Goodrich S, Kusser K, et al. Regulation of dendritic cell trafficking by the ADP-ribosyl cyclase CD38: impact on the development of humoral immunity. Immunity 2004;20:279-291 (Pubitemid 38388230)
4. Savarino A, Bottarel F, Malavasi F, et al. Role of CD38 in HIV-1 infection: an epiphenomenon of T-cell activation or an active player in virus/host interactions? AIDS 2000;14:1079-1089
5. Savarino A, Pugliese A, Martini C, et al. Investigation of the potential role of membrane CD38 in protection against cell death induced by HIV-1. J Biol Regul Homeost Agents 1996;10:13-18 (Pubitemid 27037577)
6. Liu Q, Kriksunov IA, Graeff R, et al. Crystal structure of human CD38 extracellular domain. Structure 2005;13:1331-1339 (Pubitemid 41262100)
7. Howard M, Grimaldi JC, Bazan JF, et al. Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38. Science 1993;262:1056-1059 (Pubitemid 24035045)
8. Lee HC. Structure and enzymatic functions of human CD38. Mol Med 2006;12:317-323 (Pubitemid 46489826)
9. Savarino A, Bensi T, Chiocchetti A, et al. Human CD38 interferes with HIV-1 fusion through a sequence homologous to the V3 loop of the viral envelope glycoprotein gp120. FASEB J 2003;17:461-463
10. Savarino A, Bottarel F, Calosso L, et al. Effects of the human CD38 glycoprotein on the early stages of the HIV-1 replication cycle. FASEB J 1999;13:2265-2276
11. Dianzani U, Bragardo M, Buonfiglio D, et al. Modulation of CD4 lateral interaction with lymphocyte surface molecules induced by HIV-1 gp120. Eur J Immunol 1995;25:1306-1311
12. Jarrrow Formulas. Compositions containing anti-HIV peptides and methods for use, granted January 2008. US20040116653
13. Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative protein modeling. Electrophoresis 1997;18:2714-2723 (Pubitemid 28059943)
14. Available form: www.expasy.org
15. Available form: http://www.ddl.unimi.it/ vega/index2.htm
16. Available form: http://swift.cmbi.kun.nl/ WIWWWI/
17. Zatulovskiy E, Samsonov S, Skvortsov A. Docking study on mammalian CTR1 copper importer motifs. BMC Systems Biology 2007;1(Suppl 1):P54. Published online 8 May 2007, doi:10.1186/1752-0509-1-S1-P54
18. Savarino A. In-silico. docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate. Retrovirology 2007;4:21. Published online 20 March 2007, doi:10.1186/1742-4690-4-21 (Pubitemid 46563216)
19. Norelli S, El Daker S, Mele F, et al. Response of feline immunodeficiency virus (FIV) to tipranavir may provide new clues for development of broad-based inhibitors of retroviral proteases acting on drug-resistant HIV-1. Curr HIV Res 2008;6:306-317
20. Harada S, Koyanagi Y, Yamamoto N. Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science 1985;229:563-566 (Pubitemid 16239336)
21. Pauwels R, Balzarini J, Baba M, et al. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods 1988;20:309-321 (Pubitemid 18231639)
22. Bragardo M, Buonfiglio D, Feito MJ, et al. Modulation of lymphocyte interaction with endothelium and homing by HIV-1 gp120. J Immunol 1997;159:1619-1627
23. Savarino A, Calosso L, Piragino A, et al. Modulation of surface transferrin receptors in lymphoid cells de novo infected with human immunodeficiency virus type-1. Cell Biochem Funct 1999;17(1):47-55 (Pubitemid 29094830)
24. Savarino A, Bottarel F, Calosso L, et al. Effects of the human CD38 glycoprotein on the early stages of the HIV-1 replication cycle. FASEB J 1999;13:2265-2276
25. Savarino A, Gennero L, Chen HC, et al. Anti-HIV effects of chloroquine: mechanisms of inhibition and spectrum of activity. AIDS 2001;15:2221-2229 (Pubitemid 34059828)
26. Montefiori DC, Pellegrino MG, Robinson EE Jr, et al. Inhibition of HIV-1 proviral DNA synthesis and RNA accumulation by mismatched dsRNA. Biochem Biophys Res Commun 1989;158:943-950
27. Kempf DJ, Sham HL, Marsh KC, et al. Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy. J Med Chem 1998;4:602-617 (Pubitemid 28093094)
28. Feito MJ, Bragardo M, Bonissoni S, et al. gp120s derived from four different syncytium-inducing strains induce different patterns of CD4 association with lymphocyte surface molecules. Int Immunol 1997;9:1141-1147 (Pubitemid 27361757)
29. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005;10:1451-1458 (Pubitemid 41483874)
30. Liu J, Bartesaghi A, Borgnia MJ, et al. Molecular architecture of native HIV-1 gp120 trimers. Nature 2008;455:109-113
31. Kwong PD, Wyatt R, Robinson J. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 2008;393:648-659
32. Seddiki N, Ramdani A, Saffar L, et al. A monoclonal antibody directed to sulfatide inhibits the binding of human immunodeficienvy virus type 1 (HIV-1) envelope glycoprotein to macrophages but not their infection by the virus. Biochim biophys acta. Molecular basis of disease. 1994;1225:289-296
33. D'Cruz OJ, Uckun FM. Gel-microemulsions as vaginal spermicides and intravaginal drug delivery vehicles. Contraception 2001;64:113-123 (Pubitemid 33042598)
34. D'Cruz OJ, Uckun FM. Intravaginal toxicity studies of a gel-microemulsion formulation of spermicidal vanadocenes in rabbits. Toxicol Appl Pharmacol 2001;170:104-112 (Pubitemid 32108685)
35. Ramjee G, Doncel GF, Mehendale S, et al. Microbicides 2008 Conference: from Discovery to Advocacy. AIDS Res Ther 2008;5:19
36. 0 under 1. Review of the 3rd International Workshop on HIV Transmission: Principles of Intervention. 31 July-1 August 2008. Rev Antivir Ther 2008;In press